Samsung Biologics
27F, 1320-10, Seocho 2-dong, Seocho-gu
Seoul
137-965
Tel: 82-2-2255-8500
Fax: 82-2-2255-8577
Website: http://www.samsungbiologics.com/
104 articles with Samsung Biologics
-
Seven pharma CEOs announce new joint action to accelerate net zero healthcare
11/3/2022
CEOs from AstraZeneca, GSK, Merck KGaA, Novo Nordisk, Roche, Samsung Biologics and Sanofi announced joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
-
Samsung Biologics Reports Third Quarter 2022 Financial Results
10/26/2022
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization, released today its fiscal year 2022 third-quarter financial results, announcing that the company's cumulative revenue in fiscal year 2022 surpassed KRW 2 trillion.
-
Samsung Biologics obtains three global ISO certifications
10/13/2022
Samsung Biologics announced today it has successfully renewed its ISO 27001 certification (Information Security Management System) and obtained ISO 27017 certification (Information Security in cloud services) and ISO 37001 certification (Anti-bribery management systems).
-
Samsung Biologics unlocks additional capacity for production at its newest Plant 4
10/11/2022
Samsung Biologics announced that its Plant 4 – the world's largest single bio manufacturing plant – has commenced GMP operations this month.
-
Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022
9/29/2022
Two distinctive platforms will streamline the antibody development process. With an advanced design and high binding affinity, S-DUAL™ ensures optimized manufacturability of bispecific antibodies.
-
Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts
9/28/2022
Samsung Biologics was awarded the Gold Sustainability Rating from EcoVadis, a leading global business provider that evaluates the Corporate Social Responsibility performances of companies in areas related to environment, labor and human rights, ethics and sustainable procurement.
-
GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine
8/1/2022
GreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies’ mRNA production partnership.
-
Samsung Biologics Reports Second Quarter 2022 Financial Results
7/27/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, announced strong financial results for the second quarter of fiscal year 2022.
-
Samsung Biologics to purchase land for its second Bio Campus
7/18/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, announced that it has signed a land purchase agreement with the Incheon Free Economic Zone on July 18th to support the build out of its second Bio Campus.
-
'Sustainable CDMO' Samsung Biologics releases 2022 ESG Report
7/11/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, published its second annual ESG Report, reflecting the company's sustainability efforts in 2021 to address a wide range of environmental, social, and governance activities related to its business.
-
Most of Samsung's investment will be in South Korea, and it expects to create 80,000 new jobs through 2026, or about 16,000 positions annually.
-
A recent research report points to the CDMO market heating up. P&S projected the global biologics CDMO market would hit $31.839 million by 2030.
-
Samsung Biologics Reports First Quarter 2022 Financial Results
4/27/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, announced strong financial results for the first quarter of fiscal year 2022.
-
Samsung Biologics completes full acquisition of Samsung Bioepis
4/20/2022
Samsung Biologics announced that it has completed the purchase of Biogen's stake in the Samsung Bioepis joint venture for USD $2.3 billion.
-
Samsung Biologics holds 11th Annual General Meeting of Shareholders
3/29/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, hosted its 11th Annual General Meeting of Shareholders.
-
Samsung Biologics receives 2022 CMO Leadership Award in all six categories
2/7/2022
Samsung Biologics announced that it has been selected as a winner of the 2022 CMO Leadership Awards presented by Outsourced Pharma and Life Science Leader.
-
Biogen is selling its nearly 50% stake in Samsung Bioepis for $2.3 billion. The move will provide Biogen with additional capital while preparing to cut additional costs through a rumored employee layoff.
-
Fujifilm announced that it is acquiring Atara Biotherapeutics' cell therapy manufacturing facility in California for $100 million.
-
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results
1/24/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, announced strong financial results for the fourth quarter and record-high earnings for the fiscal year of 2021.
-
Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference
1/12/2022
Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference.